Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Effect of telmisartan on renal outcomes: a randomized trial.

Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Rydén L, Yu CM, Teo KK, Yusuf S; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators.

Ann Intern Med. 2009 Jul 7;151(1):1-10, W1-2. Epub 2009 May 18.

PMID:
19451556
2.

Telmisartan did not prevent renal disease in patients without proteinuria.

[No authors listed]

Ann Intern Med. 2009 Jul 7;151(1):I28. Epub 2009 May 18. No abstract available.

PMID:
19451555
3.

Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.

Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF; ONTARGET and TRANSCEND Investigators.

Circulation. 2011 Mar 15;123(10):1098-107. doi: 10.1161/CIRCULATIONAHA.110.964171. Epub 2011 Feb 28.

4.

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators.

Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2.

PMID:
18707986
6.

[Critically appraised article].

Neumann I, Grassi B.

Rev Med Chil. 2012 Jan;140(1):117-20. doi: /S0034-98872012000100018. Epub 2012 Apr 12. Spanish.

8.

Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies.

Aranda P, Segura J, Ruilope LM, Aranda FJ, Frutos MA, López V, López de Novales E.

Am J Kidney Dis. 2005 Dec;46(6):1074-9.

PMID:
16310573
9.
10.
11.

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group.

N Engl J Med. 2004 Nov 4;351(19):1952-61. Epub 2004 Oct 31. Erratum in: N Engl J Med. 2005 Apr 21;352(16)1731.

12.

Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.

Cice G, Di Benedetto A, D'Isa S, D'Andrea A, Marcelli D, Gatti E, Calabrò R.

J Am Coll Cardiol. 2010 Nov 16;56(21):1701-8. doi: 10.1016/j.jacc.2010.03.105.

13.

Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.

Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM.

Am J Kidney Dis. 2009 Apr;53(4):606-16. doi: 10.1053/j.ajkd.2008.11.026. Epub 2009 Feb 12.

PMID:
19216016
14.

Prevention of loss of renal function over time in patients with diabetic nephropathy.

Barnett A.

Am J Med. 2006 May;119(5 Suppl 1):S40-7. Review.

PMID:
16563947
15.

The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.

Vogt L, Navis G, Köster J, Manolis AJ, Reid JL, de Zeeuw D; Angiotensin II Receptor Antagonist Telmisartan Micardis in Isolated Systolic Hypertension (ARAMIS) Study Group.

J Hypertens. 2005 Nov;23(11):2055-61.

PMID:
16208149
16.

Telmisartan in incipient and overt diabetic renal disease.

Schmieder RE, Bakris G, Weir MR.

J Nephrol. 2011 May-Jun;24(3):263-73. doi: 10.5301/JN.2011.6416. Review.

PMID:
21374585
17.

Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study.

Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, Yusuf S, Mann JF; ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease).

Ann Intern Med. 2011 Mar 1;154(5):310-8. doi: 10.7326/0003-4819-154-5-201103010-00005.

PMID:
21357908
18.

Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.

Clase CM, Barzilay J, Gao P, Smyth A, Schmieder RE, Tobe S, Teo KK, Yusuf S, Mann JF.

Kidney Int. 2017 Mar;91(3):683-690. doi: 10.1016/j.kint.2016.09.038. Epub 2016 Dec 4.

PMID:
27927602
19.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2267-76. doi: 10.1056/NEJMoa1402686. Epub 2014 Nov 15.

20.

Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.

Ivory SE, Packham DK, Reutens AT, Wolfe R, Rohde RD, Lewis J, Atkins RC; Collaborative Study Group.

Nephrology (Carlton). 2013 Jul;18(7):516-24. doi: 10.1111/nep.12053.

PMID:
23506627

Supplemental Content

Support Center